Pharmaceutical Market Europe • July/August 2020 • 42-44
APPOINTMENTS
European Medicines Agency
EMER COOKE
The European Medicines Agency (EMA) management board has nominated Emer Cooke as its new executive director. Cooke is currently the director of the regulation and prequalification department at the World Health Organization (WHO), a position she has held since November 2016. In this role she leads WHO’s global work on health technologies regulation, including prequalification and regulatory systems. She has 30 years’ experience in international regulatory affairs, 18 years of which were in leadership roles. Cooke worked for the pharmaceutical unit of the European Commission from 1998 to 2002, and at the EMA between 2002 and 2016, where she held positions including head of inspections and head of international affairs. Cooke gained a degree in pharmacy from Trinity College Dublin in Ireland and has Masters degrees in science and business administration.
Gilead
MARK GENOVESE
Gilead has appointed Mark Genovese as senior vice president, inflammation. In this role, Genovese will oversee the clinical development of Gilead’s investigational portfolio of treatments for inflammatory conditions. He joins from Stanford University, where he most recently served as the James W. Raitt professor of medicine and clinical chief in the division of immunology and rheumatology.
NHS Confederation
DANNY MORTIMER
Danny Mortimer has been appointed as the interim chief executive of the NHS Confederation, after current chief exec Niall Dickson announced he would be stepping down from the post after almost four years. Mortimer had served as chief executive of NHS Employers, but will step down from that role to take the helm at NHS Confederation.
BeiGene
ANGUS GRANT
BeiGene has appointed Angus Grant as chief business executive. Most recently, Grant was chief executive officer of the Dementia Discovery Fund (DDF), a specialist venture capital fund focused on therapeutics for age-related dementias and neurodegenerative disease. Prior to DDF, Grant spent 12 years at Celgene in a range of leadership roles including corporate vice president of business development.
Mundipharma
MARC PRINCEN
Mundipharma has appointed Marc Princen as its new global chief executive officer. Princen was most recently president and executive vice president, international business, at Allergan International. He brings more than 30 years of cross-functional experience in the pharmaceutical industry to Mundipharma, with a particular expertise in commercial, marketing, business development and management.
Moderna
DAVID MELINE
Moderna has appointed David Meline as its new chief financial officer (CFO). Meline joins Moderna from Amgen, where he served as CFO and executive vice president from 2014 until 2019. Prior to Amgen, he spent six years at 3M Company, where he served as CFO and senior vice president and was responsible for the companies financial activities across 70 countries.
Dewpoint Therapeutics
OLIVIER BRANDICOURT
Dewpoint Therapeutics has appointed Olivier Brandicourt to its board of directors. Brandicourt is a seasoned pharmaceutical industry leader, having served as chief executive officer of both Sanofi and Bayer. Prior to that, he held a series of leadership roles at Pfizer, including a stint as president and general manager of the emerging markets and established products units.
Dewpoint Therapeutics
JÜRGEN ECKHARDT
Dewpoint Therapeutics has also appointed Jürgen Eckhardt to its board of directors. Eckhardt is a veteran biopharmaceutical investor, and currently serves as senior vice president and head of Leaps by Bayer, the impact investment unit of Bayer AG. In addition to his role at Bayer, he serves on the boards of several innovative biotechnology companies.
Amolyt Pharma
PIERRE LEGAULT
Amolyt Pharma has appointed Pierre Legault as director and chairman of its board of directors. Legault brings over 35 years of executive leadership experience in the biopharmaceutical and pharmaceutical industries to the role. In addition to his role at Amolyt, Legault also serves as the chairman of Artios Pharma, Bicycle Therapeutics and Poxel Pharma.
Norgine
CHRISTOPHER BATH
Christopher Bath has been appointed chief operating officer of Norgine. Bath has served as Norgine’s chief financial officer since 2014 and in his new role as COO he will be responsible for all global operations. He joined Norgine from Shire, where he served as head of mergers and acquisitions, and began his career at Rothschild.
STORM Therapeutics
JOSEFIN-BEATE HOLZ
STORM Therapeutics has appointed Josefin-Beate Holz as chief medical officer. Holz has over 25 years of experience in pharmaceutical drug development in Europe and North America. She has held executive managerial positions at international pharmaceutical and biotech companies Ablynx, GPC-Biotech, Gilead Sciences, Bristol-Myers Squibb and LEO Pharma.
Azafaros
KYLE LANDSKRONER
Kyle Landskroner has joined Azafaros as head of preclinical drug development. Previously, Landskroner worked as director, global integration and separation office at Novartis from 2017, where he also served as director, portfolio management, global drug development, portfolio strategy and innovation. Prior to that, he was a senior laboratory head at Actelion Pharmaceuticals.
Azafaros
RUBEN GIORGINO
Azafaros has also appointed Ruben Giorgino as head of clinical research and development. He brings over 20 years of experience to the company and previously held the position of global head of clinical research and development of the Helsinn Group. Prior to Helsinn, Giorgino held global clinical development and medical affairs leadership roles at Actelion Pharmaceuticals.
Azafaros
LOUISE KOOIJ
Louise Kooij also joins Azafaros as head of finance and operations. Kooij joins from Sanofi-Genzyme, where she served as head of rare disease, Central and Eastern Europe. Prior to this, she held the position of head of business operations, Europe at Sanofi-Genzyme, after working as vice president, business control and analysis at Sanofi-Genzyme in Boston, US.
Orion Group
OUTI VAARALA
Outi Vaarala has been appointed senior vice president for research and development and a member of the executive management board of the Orion Group. Vaarala has held the position of vice president, oncology research in Orion’s research and development division since June 2019. Prior to Orion, she led drug discovery and development in respiratory inflammation and autoimmunity therapy areas at AstraZeneca and Medimmune.
Exact Therapeutics
OUTI VAARALA
Exact Therapeutics has appointed Rafiq Hasan as its new chief executive officer. Most recently, Hasan worked as senior vice president and global head of ophthalmology at Bayer, and also held several other senior positions within Bayer and Novartis. He gained his medical degree in London, and has since pursued a career in the pharmaceutical industry globally.
Elekta
RUBEN GIORGINO
Elekta has appointed Gustaf Salford as acting president and chief executive officer, after current president and CEO Richard Hausmann resigned. Salford has held senior management positions in Elekta for eleven years, including most recently as executive vice president and chief financial officer. Prior to Elekta, he gained broad financial experience from Boston Consulting Group and Booz Allen Hamilton.
Mogrify
LORENZ MAYR
Lorenz Mayr has been appointed to Mogrify’s board of directors and scientific advisory board. Mayr has over 30 years of experience in biopharma research, development and commercialisation. Most recently, he served as chief technical officer at GE Healthcare Life Sciences, and his previous industry roles include vice president & global head at AstraZeneca and executive director at Novartis.
SOTIO
RICHARD SACHSE
SOTIO has appointed Richard Sachse as chief medical officer. Sasche has more than 25 years of experience in the biopharma industry as a physician and scientist. Most recently, he served as the deputy chief medical officer of SOTIO, and has also held positions at Bayer, Boehringer Ingelheim, Aeterna Zentaris and Neovii Pharmaceuticals at various levels of management.
GENFIT
ERIC BACLET
Eric Baclet has been appointed to GENFIT’s board of directors. Baclet has over 30 years of experience, gained from working at Eli Lilly. At Eli Lilly, he worked across international drug development, management and commercialisation. He served as president and general manager of Lilly Italia, general manager of Lilly China and also vice president of global marketing.
GENFIT
KATHERINE KALIN
GENFIT has also appointed Katherine Kalin to its board of directors. Currently, Kalin is a director on the boards of Clinical Genomics, Brown Advisory and Primari Analytics. From 2012 to 2017, Kalin led corporate strategy at Celgene, and prior to that she held executive leadership roles in marketing, sales, strategy and new business development at Johnson & Johnson.
Syneos Health
TIM PANTELLO
Tim Pantello has joined Syneos Health as president of communications, where he will lead the combined portfolio business. Pantello has nearly 25 years of experience in marketing, strategy and technology, and is the ideal candidate to lead the next generation of communications experts. Prior to Syneos, he was managing director at PricewaterhouseCoopers (PwC).
Syneos Health
IAN DORRIAN
Ian Dorrian has also joined Syneos Health as its president of EU communications, bringing more than 20 years of agency experience to the role. That experience spans independent firms, major holding companies, as well as regional and global roles. Previously he worked in the pharmaceutical industry for ten years, gaining experience in medical affairs and field sales.
HCA
ALICE CHOI AND EMMA KENNY
The Healthcare Communications Association (HCA) has announced its new board structure, with Alice Choi confirmed as board chair and Emma Kenny as a board member and committee chair. Choi is currently chief operating officer of McCann Health Medical Communications. Kenny, a partner and operations director at AXON Communications, has over 20 years of experience.
HCA
EDEL MCCAFFREY AND ANNABELLE SANDEMAN
Edel McCaffrey and Annabelle Sandeman have been confirmed as board members and committee chairs of the HCA. McCaffrey, an independent communications consultant, has over 25 years of corporate and healthcare comms experience. Sandeman is global head of commercial strategy for Hunstworth, with over 20 years of experience.
Syneos Health
JD CASSIDY
Also joining the team at Syneos Health is JD Cassidy, who has been appointed president of advertising, North America. Cassidy joins from Saatchi & Saatchi Wellness, where he served as president, simultaneously growing revenue and employee engagement. He has worked on multiple brands and therapeutic categories, and also has omnichannel expertise across patients, providers and payers.
Syneos Health
MARIA TENDER
Maria Tender is set to lead strategy and planning for Syneos Health Communications as its new head of strategy. She joins from DDB where, for more than two decades, she led strategy and planning and built the healthcare strategy group. At DDB, she oversaw new business development across a range of sectors, including large pharmaceutical companies across numerous therapeutic areas.
OPEN Health
JEFF ANDERSON
OPEN Health has appointed Jeff Anderson as its European lead for the combined business across OPEN VIE and Pharmerit Europe. Anderson joins OPEN Health with a wealth of global experience across a range of key areas. Previously, he served as director of consulting, innovation and knowledge transfer and as a senior research fellow at ScHARR (University of Sheffield).
W2O
TOM RICHARDS
W2O has appointed Tom Richards as co-global chief creative officer of its healthcare firm 21GRAMS. Richards joins 21GRAMS from healthcare communications agency Havas Lynx, where he served as chief creative officer. In addition, he is also currently president of the Health and Wellness jury at Cannes Lions International Festival of Creativity, which he will continue to lead until 2021.
HCA
ALISTAIR SANSUM AND JO TAYLOR
Alistair Sansum and Jo Taylor have also joined as HCA board members and committee chairs. Sansum is currently the director of scientific and medical communications at Publicis Health, based in London. Taylor is currently the director of Cello Health Communications in Europe, and has worked in healthcare communications for over 25 years.
Health Unlimited
CLARE PECK
Health Unlimited has appointed its long-serving team member Clare Peck to the new role of managing director. Peck has been with Health Unlimited for 11 years and in her new role as MD she will advance business performance and provide strategic leadership for the growing agency. She will also join the board of the agency’s communications division.
P\S\L Group
PAUL O’SHAUGHNESSY
P\S\L Group has appointed Paul O’Shaughnessy as managing director of its RxY business. Prior to P\S\L, O’Shaughnessy served as executive vice president, global sales at M3 and also held the position of global head of business development at Cello Health. He has also served as director, business development at Branding Science and international business director at GfK.
Kanga Health
PAUL ALLEN
Kanga Health has promoted Paul Allen to the role of studio and project director. Allen will also join the board of directors and become a member of the agency’s executive management team. In this role, he will be responsible for the successful delivery of all client projects. He brings over 20 years of experience to the role.